ViiV Healthcare, global specialist HIV company owned by GlaxoSmithKline (GSK), has announced an exclusive collaboration with Shionogi & Co Ltd (Shionogi) to develop a third-generation HIV integrase inhibitor (INSTI), with potential for ultra-long-acting dosing intervals.
